Through partnerships with leading companies, Cellspect is bringing the next generation of medical technology to a more people.In particular, products brought to market utilizing Point Of Testing and Precision Oncology for Customized Treatment are expected to improve diagnostic accuracy in healthcare access issues. As part of Cellspect's growth strategy, we are strengthening our partnerships with major pharmaceutical companies and medical institutions in Japan and abroad, as well as with industry, academia, and government, in order to achieve synergies between technological innovation and market expansion.Through these efforts, we plan to expand our share of new markets and achieve sustainable growth as well as the diffusion of new items. We will provide collaborative projects as QMS-compliant open innovation at any step of the diagnostics commercialization scheme. We can also flexibly provide comprehensive collaboration projects including development of new items, manufacturing and sales, and distribution at the early stage.
Please contact us if you are interested in open innovation for biomarkers.